Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in topical-treatment-resistant mild to moderate psoriasis
IRCT20150716023235N18Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of omalizumab in psoriasis (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Psoriasis Area and Severity Index. Started Sep 2023; status: completed.
02
Drugs
omalizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on IRCT20150716023235N18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150716023235N18.